I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Lars Fruergaard Jørgensen net worth and biography

Lars Jørgensen Biography and Net Worth

President of Novo Nordisk A/S

Mr. Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, the US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over the responsibilities for Corporate People & Organisation and Business Assurance and became chief of staff. Mr Jørgensen was appointed president and chief executive officer in January 2017.

Mr. Jørgensen serves as First Vice-President at the European Federation of Pharmaceutical Industries and Associations (EFPIA).

How do I contact Lars Fruergaard Jørgensen?: The corporate mailing address for Mr. Jørgensen and other Novo Nordisk A/S executives is Novo Alle, Bagsvaerd G7, 2880. Novo Nordisk A/S can also be reached via phone at (454) 444-8888 and via email at [email protected]. Learn More on Lars Fruergaard Jørgensen's contact information.
Has Lars Fruergaard Jørgensen been buying or selling shares of Novo Nordisk A/S?: Lars Fruergaard Jørgensen has not been actively trading shares of Novo Nordisk A/S within the last three months. Learn More on Lars Fruergaard Jørgensen's trading history.
Who are Novo Nordisk A/S's active insiders?: Novo Nordisk A/S's insider roster includes Lars Jørgensen (President), Karsten Knudsen (Exec. VP), and Marcus Schindler (EVP). Learn More on Novo Nordisk A/S's active insiders.

Lars Fruergaard Jørgensen Insider Trading History at Novo Nordisk A/S

Lars Fruergaard Jørgensen Buying and Selling Activity at Novo Nordisk A/S

Novo Nordisk A/S Company Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Today's Range

Now: $110.25

$109.96

$110.88

50 Day Range

MA: $112.81

$99.82

$126.95

2 Week Range

Now: $110.25

$94.73

$148.15

Volume

1,851,595 shs

Average Volume

4,499,741 shs

Market Capitalization

$494.75 billion

P/E Ratio

35.68

Dividend Yield

0.68%

Beta

0.4

I was wrong. Dead wrong.

From Porter & Company | Ad